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Abstract
The simple boronated bases, e.g. cytosine, adenine and guanine,
containing no sugar residues retained good pharmacological activity as
hypolipidemic, anti-neoplastic and anti-inflammatory agents in mice at 8
mg/kg. Their activities were generally identical to their respective
nucleoside derivatives. Interestingly the boronated acyclovir derivative
was a very potent hypolipidemic agent achieving better activity than
clofibrate and lovastatin. The boronated adenine derivatives appeared
to have the best anti-inflammatory activity in reducing local edema and
analgesic effects. The agents were ctive against the growth of murine
and human leukemias and human HeLa-S suspended uterine carcinoma. Only
the boronated adenine derivatives were effective in blocking the growth
of human SW480 adenocarcinoma and the KB nasopharynx.
Introduction
The anti-neoplastic activity of 2’-deoxynucleoside-cyanoboranes
1’z has
previously been reported The original derivatives had the boron atom
placed or attached on the nitrogen of guanosine, adenosine, inosine and
cytidine nucleoside. The cytidine boronated nucleosides were the most
potent antineoplastic/cytotoxic agents’. Further pharmacological testing
showed that these boronated nucleosides also possessed hypolipidemic
3 as
well as anti-inflammatory/anti-septic shock properties Subsequently,
two thymidine boronated nucleosides were examined5. These derivatives
had the boron moiety attached to the 5 -hydroxyl group of the
deoxyribose sugar and possessed all three types of pharmacology
activities. The derivatives were effective in reducing DNA and protein
syntheses in L-1210 cells with inhibition of ribonucleoside reductase,
dihydrofolate reductase, purine de novo synthesis and depending on the
substituted moiety, DNA polymerase , and the RNA polymerase
activities, d[NTP] pool levels were significantly reduced after 60
min. Boronated guanine and adenosine arabinoside, deoxyribose and
ribose also demonstrated potent cytotoxic action’. The boronated
adenosine arabinoside demonstrated very potent activity as an anti-
neoplastic agent inhibiting purine synthesis and DNA synthesis but more
important was the observation that it was a DNA topoisomerase II
inhibitor with DNA strand scission4. Carborane moieties added in the
5’-hydroxyl group of the sugar residue have also demonstrated potent
cytotoxic action. All of these boronated nucleosides agents have proven
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to be safe at their therapeutic dose in mice. The current study is an
investigation of the boronated bases without any sugar moieties to
determine their activity as cytotoxic, hypolipidemic and as anti-
inflammatory agents
Materials and Methods
Source of compounds
The compounds (see Fig. 1) were synthesized by a Lewis base exchange
reaction described previously. All radioisotopes were purchased from
New England Nuclear (Boston, MA) unless otherwise indicated.
Radioactivity was determined in Fisher Scintiverse scintillation fluid
with correction for quenching. Substrates and cofactors were obtained
from Sigma Chemical Co. (St. Louis, MO).
Pharmacological methods
Hypolipidemic activity: CFI male mice (-28g) were administered compounds
in I%CMC at 8 mg/kg/day, I.P. Blood samples were obtained on days 9 and
16 between 7:30 and 8:30 a.m. Daily dosing of the agents was between
9:00 and 10:00 a.m. the serum was obtained by centrifuging the blood
for i0 min. at 3500 g. The serum cholesterol levels were determined by a
modification of the Liebermann-Burchard procedure 9. Serum triglyceride
were determined using a commercial kit Boehringer Mannheim
Diagnostics]
Cytotoxicity assays: Compounds 1-9 were tested for cytotoxic activity by
homogenizing drugs in a 1 mM solution in 0.05% Tween 80/H20. These
solutions were sterilized by passing them through an acrodisc filter
45 The following cell lines were maintained by literature
techniques murine LI210 lymphoid leukemia, human Tmolt 3 acute
lymphoblastic T cell leukemia, colorectal adenocarcinoma SW480, HCT-8
ileum adenocarcinoma, lung bronchogenic MB-9812, osteosarcoma TE418, KB
epidermoid nasopharynx, HeLa-S3 suspended cervical carcinoma, and glioma
EH 118 MG. Geran et al. ’s protocol was used to assess the
cytotoxicity of the compounds and standards in each cell line. Values
for cytotoxicity were expressed as EDs0 Ng/ml, i.e. the concentration
of the compound inhibiting 50% of cell growth. ED50 values were
determined by the trypan blue exclusion technique. A value of less than
4 g/ml was required for significant activity of growth inhibition.
Solid tumor cytotoxicity was determined by utilizing crystal violet/MeOH
and read at 580 nm (Molecular Devices) ’2.
Anti-neoplastic activity: In vivo antineoplastic activity was tested in
the Ehrlich ascites carcinoma screen in CFI male mice[-28g]. On day zero
2 X i0 Ehrlich ascites carcinoma cells were injected I.P. into the
mice. Drugs were prepared on 0.05 Tween 80/water and administered I.P.
on days 1-9. On day i0, the surviving animals were sacrificed and the
tumor volume and astrocrit determined and the percent inhibition of
tumor calculated
Anti-inflammatory screen: Male CF1 mice weighing 28-32g obtained from
Jackson Lab. [Bar Harbor, MA] were administered agents at 8 mg/kg X 2
I.P. administered 3 hr and 30 min prior to administering the irritant,
according to Winter’s protocolI’. Evaluation of the induced edema was
made by injecting 2% carrageenan in 0.9% saline into the plantar region
of the foot I’. The opposite foot injected with 0.9% saline was used as a
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base line. The standards indomethacin (I0 mg/kg) and phenylbutazone (50
mg/kg) were used to compare activity.
Endotoxic shock: Protection against septic shock: CF1 male mice (29-
31g) were administered lipopolysaccharides[LPS] Salmonella abortus equi
iLot # 69F4003] at 10 mg/kg, I.P which has an LD100 within 48-52 hr which
was consistent with literature values I". Drugs were administered 2 hr
prior and 2 hr post-injection of the LPS and the subsequently every 24
hr for the length of the animals’ lives. Deaths were recorded every 12
hr and continued for 96 hr. Indomethacin (8 mg/kg) and pentoxyfylline
(50 mg/kg) were used as standards.
Local analgesic activity: CF 1 male mice (28.5-32g) were administered
agents at 8 mg/kg I.P. 20 min before 0.5 mL of 0.6% acetic acid was
administered I.P. After 5 min, the number of stretches were counted
over the next i0 min. Indomethacin was used as a standard at 8 mg/kg.
Hot plate tail flick screen: CF 1 male mice (29-32g) were administered
drugs at 8 mg/kg, I.P. prior to placement on a hot plate maintained at
100F. Time elapsed prior to tail raising was measured using a digital
read-out connected to the hot plate I<’. Tail flick responses of CF 1 mice
injected with morphine were used as the standard for this assay.
Results
The boronated purine and pyrimidine bases maintained good activity in
the hypolipidemic, cytotoxicity and anti-inflammatory screens suggesting
that a nucleoside form of the boronate base is not always necessary for
good pharmacological activity.
Table i. The Hypolipidemic Activity of Boronated Pyrimidine and Purine
Derivatives in CF 1 Male Mice at 8 mg/kg/day, I.P.
Percent Control N 6]
Compound # Serum Cholesterol Serum Triqlyceride
Day 9 Day 16 Day 16
Control 100+/-6 i00+/-6c i00+/-5d
1 88+/-5 73+/-5* 86+/-4
2 75+/-3* 72+/-4* 95+/-5
3 87+/-6 70+/-3* 78+/-4*
4 87+/-5 71+/-3" 104+/-6
5 77+/-3* 59+/-4* 66+/-4*
6 68+/-4* 62+/-4* 51+/-3"
7 89+/-6 84+/-5 88+/-6
8 67+/-4* 62+/-4* 42+/-5*
9 78+/-5* 51+/-6, 59+/-6*
Clofibratea 87+/-6 78+/-6* 75+/-6*
Lovastatinb 85+/-4 82+/-5 86+/-7
*p 0.001 Student’s "t" test; a 150 mg/kg/day; b 8 mg/kg/day, c
125mg/dL; d 137 mg/dL.
The cytosine derivatives [5,6,8] were better hypolipidemic agents than
the simple adenine or guanine derivatives [I-__4]. Compounds 5 and 7 do
not contain a boron moiety yet they demonstrated significant activity.
The boronated acyclovir, compound 9, is a guanine derivative and
demonstrated potent activity. Compounds 1-4 lowered serum cholesterol
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level on day 16, 27-30% and only compounds 1 and 4 lowered serum
triglyceride levels 22% on day 16 at 8 mg/kg/day. Compounds 5-9 lowered
serum cholesterol levels 38-48% and serum triglycerides 34-58%. These
derivatives demonstrated activity that was superior to the standards
clofibrate at 150 mg/kg/day and lovastatin at 8 mg/kg/day The methylated
boronated cytosine demonstrated the best overall hypolipidemic
activity.
The in vivo anti-neoplastic activity in the Ehrlich ascites carcinoma
screen showed that compounds 1-3 afforded 40%, 50%, 40% inhibition and
5, 7 and 9 were inactive. Compounds 4, 6 and 8 afforded 62%, 78% and
77% reduction of ascites tumor growth in mice at 8 mg/kg/day I.P.
Table 2 Cytotoxicity of Pyrimidine and Purine Bases
EDs0 values g/ml
L-1210 Tmolt3 HeLa- KB Skin Adenocarcinoma Lung Osteo Glioma
’d Leukemias S3 Solid Naso- A431 Colon Ileum A549 M9812 Bone Brain Cp
1 1.29 1.98
2 1.89 2.46
3 1.59 1.51
4 1.06 0.82
5 6.81 3.87
6 3.82 0.91
7 4.42 3.37
8 3.04 1.43
9 1.2- 2.34
5FU 1.41 2.14
AraC 2.76 2.67
Hydroxyurea
2.67 3.18
6MP 2.42 1.62
Uterine pharynx SW-480 HCT-8 Sarcoma
0.98 2.34 2.86 3.18 1.61 7.98 4.09 6.02 7.88
2.86 5.87 3.65 3.70 3.17 7.84 5.15 6.74 7.38
1.38 5.33 3.82 6.19 1.08 7.44 5.07 6.41 7.81
0.76 8.32 4.91 2.53 7.76 7.89
5.54 6.43 7.62 7.84 9.91 9.10 8.46 7.80
I. 97 7.16 5.87 7.05 9.19 i. 42 8.84 8.81
5.48 7. ii 5.26 6.69 9.30 8.58 7.74 8.80
I. 64 7. ii 5.26 6.69 9.30 1.67 7.74 8.72
0.87 8.67 2.52 i0.2 5.96 8.30 I0.23 5.88
2.47 4.11 1.25 1.12 3.09 0.61 3.58 5.64 3.52 1.28
2.13 4.74 2.84 2.54 3.42 0.92 4.69 6.16 0.86 1.88
1.96 8.12 5.29 1.77 4.74 3.21 7.37 7.18 2.87
2.12 5.61 11.04 3.61 3.61 3.42 4.71 4.29 9.39
2.57
4.46
The cytotoxicity screens showed that the adenine derivatives were all
active in the L-1210 leukemia screen with EDs0 values 54 g/ml.
The boronated acyclovir derivative was also very active, but the
cytidine derivatives without the cyano-boron moiety were not as active.
The two cytidine derivatives 6__ and with the boron moiety were
marginally active with EDs0 values -3.0 Mg/ml. All of the compounds were
active against Tmolt 3 T cell leukemia growth. The non-boronated
cytidine derivatives and [ were only marginally active. Compounds
and afforded ED-50 values >i Mg/ml. In the HeLa-S 3 uterine suspended
tumor screen all of the boronated compounds were active with compounds
l, , and affording ED-50 values less than <i g/ml. However, only
compound was active against the growth of the solid HeLa uterine
carcinoma. In the KB nasopharynx screen compounds , , , and were
active and in the skin epidermoid carcinoma screen compound ! and were
marginally active. Colon adenocarcinoma SW480 growth was reduced by
compound !-, only with compound demonstrating the best activity
resulting in an ED0 value of 1.08 Mg/ml. None of the compounds were
active against HCT-8 ileum adenocarcinoma, lung A549 carcinoma,
osteosarcoma and glioma growth. In the lung bronchogenic MB-9812 only
compounds and 8__demonstrated ED50 values of less than 2 g/ml.
158LH. Hall, B.S. Burnham, A. Elkins, A. Sood,
W. Powell, J. Tomasz and B.F. Spielvolgel
Metal-BasedDrugs
In the anti-inflammatory screen compounds I-3 and 6 at 8 mg/kg caused
44-51% inhibition of induced edema in mice. The remaining compounds were
not active at 8 mg/kg X 2 in mice. Compound 3 was also active in the
septic shock assay since it offered 66% protection at 4 or 8 mg/kg/day
from death induced by LPS and was equally active as the standards
petoxfylline at 50 mg/kg/day and dexamethasone 1 mg/kg/day. Compounds I-
3 inhibited the writhing reflex for local pain at 8 mg/kg and increased
the tail flick assay indicative of the ability to block central pain but
the compounds were not as active as morphine in this assay.
Table 3 Anti-inflammatory Activity of the Boronated Pyrimidines and
Purines in CF mice at 8 mg/kg I.P.
[N 6]
Compound #
1
2
3
4
5
6 50+/-4*
7 94+/-6
8 76+/-4*
9 72+/-5*
Indomethacin @ 8mg/kg 22+/-5*
Phenylbutazone@50 mg/kg 53+/-4*
Pentoxyifylline@ 50 mg/kg70+/-5*
Dexamethasone @ 1 mg/kg
Morphine @ 1 mg/kg
Control 100+/-6
Percent Control
Inflammation Writhing Tail
Screen Reflex
56+/-5* 13+/-2"
49+/-4* 18+/-4"
51+/-4" 59+/-5*
104+/-6
105+/-5
Protection
Flick Septic Shock
147 55
151 66
142 66
213
33
67
67
Discussion
The simple bases without the ribose, deoxyribose or arabinose but having
a cyanoborane moiety still maintained pharmacological activity in murine
human tissue cultured cancer screens and in the in vivo Ehrlich screen
at 8 mg/kg/day I.P. The adenine and guanine cyanoboranes demonstrated
approximately the same cytotoxicity as their respective nucleoside
derivatives. The adenine base where the cyanoborane moiety is on N3
maintained as good activity against the growth of those tumors as those
derivatives with the cyanoborane moiety in position N1 or N7. In the
cytosine series the lack of the cyanoborane moiety cause the loss of
cytotoxic action and an addition methyl group in the N3 position was not
effective in improving the activity. The boronated acyclovir derivative
maintained good activity in the suspended tumor cell lines but was
inactive against the solid tumor lines and in the in vivo screen.
In the anti-inflammatory screen a similar pattern was observed. The
cyanoborane moiety was required for activity. A methyl substitution in
the N3 position reduced the ability to block induced edema.
Surprisingly, the guanine bases were able to function as analgesic
agents and blocked septic or endotoxic shock induced by LPS. This was
impressive in that these simple bases were equal in action to standard
agents used in the clinic to protect against death from bacterial,
viral, AIDS related terminal infections from septic shock.
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All of the agents were effective in the hypolipidemic screens lowering
serum cholesterol and in some cases serum triglyceride levels. The
boronated acyclovir derivative possessed better activity than the
cyanoboronated guanine. The guanine and adenine derivatives were not as
active as the cytosine bases but the cyanoborane moiety was not needed
by these bases to afford good activity in lowering both serum lipid
levels
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